Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 3/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9938861 | 0.90 | KDM4E (0.68) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1663955 | 0.89 | KDM4E (0.71) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2953028 | 0.85 | KDM4E (0.89) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL572541 | 0.85 | KDM4E (0.67) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30402766 | 0.85 | KDM4E (0.67) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13610145 | 0.84 | ALDH1A1 (0.66) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL375580 | 0.83 | KDM4E (0.68) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29788583 | 0.83 | KDM4E (0.68) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1605174 | 0.83 | KDM4E (0.74) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3381012 | 0.83 | KDM4E (0.64) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-8168651-B2 | Protein kinase modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168651-B2 | Protein kinase modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-09-24 | — | — | US | disclosed |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-09-24 | — | — | US | disclosed |
| WO-2009108912-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| EP-2061768-A2 | IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | Exelixis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008042282-A2 | IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | EXELIXIS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008042282-A2 | IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | EXELIXIS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | KDM4E 952/4885ALDH1A1 4295/4885NPC1 3307/4885 |
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | KDM4E 736/4885ALDH1A1 3801/4885NPC1 4507/4885 |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | KDM4E 736/4885ALDH1A1 3801/4885NPC1 4507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.